Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

VSTMVerastem, Inc.Signing up patients

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Pancreatic Ductal Adenocarcinoma · Non Small Cell Lung Cancer · Colorectal Cancer · Solid Tumor, Adult · G12D Mutated KRAS

12Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • A key executive is leaving

    Since Oct 14, 2026 · was worth 15, fading over time

    +11.5
Worry score12

Score over time

Stage
Phase 1/2
Patients
616 (planned)
Started
Jun 24, 2025
Main results expected
Dec 2028
Fully finished
Dec 2028
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375

    Measured over: Up to 2.5 years

  • Part A: To identify the MTD or MFD

    Measured over: Cycle 1 (each cycle is 21 days)

  • Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen

    Measured over: Up to 2.5 years

  • Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.

    Measured over: From enrollment to the end of treatment; an average of 9 months

  • Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375.

    Measured over: Cycle 1 (each cycle is 21 or 28 days)

  • Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C

    Measured over: Up to 2.5 years

  • Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinide

    Measured over: Up to 2.5 years

  • Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinide

    Measured over: 2.5 years

  • Part E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substrates

    Measured over: 2.5 years

  • Part F: Serial biopsy

    Measured over: Up to 2.5 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing

Raw record changes

  • none yet

Trial ID NCT07020221 · record last updated 2026-10-23 · checked 2026-11-09 15:36 UTC

See the official record on ClinicalTrials.gov (NCT07020221) ↗